The anti-inflammation and pharmacokinetics of a novel alkaloid from Portulaca oleracea L.

Journal of Pharmacy and Pharmacology

Volumn 68, Issue 3, 2016, Pages 397-405

  Meng, Yihan ^a   Ying, Zheming ^a   Xiang, Zheng ^b   Hao, Dong ^a   Zhang, Wenjie ^a   Zheng, Yu ^a   Gao, Yucong ^a   Ying, Xixiang ^a  

^a LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b HARBIN UNIVERSITY OF COMMERCE   (China)

Author keywords

anti inflammation; oleracone; pharmacokinetics; rat plasma; ultra high performance liquid chromatography

Indexed keywords

ALKALOID DERIVATIVE; ANTIINFLAMMATORY AGENT; BERGAPTEN; CYTOKINE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRITE; OLERACONE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ALKALOID; PLANT EXTRACT;

ABSORPTION RATE CONSTANT; ALPHA HALF LIFE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BETA HALF LIFE; CELL LINE RAW 264.7; CELL STIMULATION; CENTRAL VOLUME OF DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DISTRIBUTION HALF-LIFE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RESOLUTION ELECTROSPRAY IONIZATION MASS SPECTROMETRY; MACROPHAGE ACTIVATION; MALE; MAXIMUM PLASMA CONCENTRATION; MTT ASSAY; NONHUMAN; PERIPHERAL VOLUME OF DISTRIBUTION; PLASMA CONCENTRATION-TIME CURVE; PORTULACA OLERACEA; PROSTAGLANDIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; RAT; SPECTROPHOTOMETRY; STRUCTURE ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TWO DIMENSIONAL ELECTROPHORESIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION STUDY; VOLUME OF DISTRIBUTION AT STEADY-STATE; X RAY DIFFRACTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLAMMATION; MACROPHAGE; METABOLISM; MOUSE; ORAL DRUG ADMINISTRATION; PORTULACA; PROCEDURES; TANDEM MASS SPECTROMETRY; WISTAR RAT;

ADMINISTRATION, ORAL; ALKALOIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INFLAMMATION; MACROPHAGES; MALE; MICE; PLANT EXTRACTS; PORTULACA; RATS; RATS, WISTAR; TANDEM MASS SPECTROMETRY; X-RAY DIFFRACTION;

EID: 84959449805     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12526     Document Type: Article

References (26)

1. Pharmacopoeia Committee of P.R. China, ed. Chinese Pharmacopoeia. Beijing: Chemical Industry Publishing House Press, 2010; p 46.
2. Xin HL, et al,. Two novel triterpenoids from Portulaca oleracea L. Helv Chim Acta 2008; 11: 2075-2080.
3. Awad N,. Lipid content and antimicrobial activity of phenolic constituents of cultivated Portulaca oleracea L. Bull Fac Pharm Cairo Univ 1994; 1: 137-142.
4. Xu X, et al,. Determination of flavonoids in Portulaca oleracea L. by capillary electrophoresis with electrochemical detection. J Pharm Biomed Anal 2006; 2: 493-499.
5. Tian JL, et al,. Two new alkaloids from Portulaca oleracea and their cytotoxic activities. J Asian Nat Prod Res 2014; 3: 259-264.
6. Xiang L, et al,. Alkaloids from Portulaca oleracea L. Phytochemistry 2005; 21: 2595-2601.
7. Yang Z, et al,. Phenolic alkaloids as a new class of antioxidants in Portulaca oleracea. Phytother Res 2009; 7: 1032-1035.
8. Liu D, et al,. Two antioxidant alkaloids from Portulaca oleracea L. Helv Chim Acta 2011; 3: 497-501.
9. Oh KB, et al,. Detection of antifungal activity in Portulaca oleracea by a single-cell bioassay system. Phytother Res 2000; 5: 329-332.
10. Abdel Moneim AE,. The neuroprotective effects of purslane (Portulaca oleracea) on rotenone-induced biochemical changes and apoptosis in brain of rat. CNS Neurol Disord Drug Targets 2013; 6: 830-841.
11. Zhao R, et al,. Antitumor activity of Portulaca oleracea L. polysaccharides against cervical carcinoma in vitro and in vivo. Carbohydr Polym 2013; 2: 376-383.
12. Pyee Y, et al,. Suppression of inflammatory responses by handelin, a guaianolide dimer from Chrysanthemum boreale, via downregulation of NF-kappaB signaling and pro-inflammatory cytokine production. J Nat Prod 2014; 4: 917-924.
13. Kvietys PR, et al,. Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. Free Radic Biol Med 2012; 3: 556-592.
14. Fujihara M, et al,. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther 2003; 2: 171-194.
15. Sica A, et al,. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 3: 787-795.
16. Comalada M, et al,. MKP-1: a critical phosphatase in the biology of macrophages controlling the switch between proliferation and activation. Eur J Immunol 2012; 8: 1938-1948.
17. Zamora R, et al,. Inducible nitric oxide synthase and inflammatory diseases. Mol Med 2000; 5: 347-373.
18. Hitoshi T, et al,. The preparation of pyrrolotropones from furotropones. Bull Chem Soc Jpn 1980; 53: 3373-3374.
19. Chan K, et al,. The analgesic and anti-inflammatory effects of Portulaca oleracea L. subsp. Sativa (Haw.) Celak. J Ethnopharmacol 2000; 3: 445-451.
20. MacMicking J, et al,. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-350.
21. Mosser DM, et al,. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 12: 958-969.
22. Fujiwara N, et al,. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy 2005; 3: 281-286.
23. Ricciardolo FL,. Multiple roles of nitric oxide in the airways. Thorax 2003; 2: 175-182.
24. Xu N, et al,. Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders. Mediators Inflamm 2015; 00: 1-10.
25. Kaplanski G, et al,. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003; 1: 25-29.
26. Ricciotti E, et al,. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 5: 986-1000.